Vanessa is a Senior Associate on the Life Sciences team and focuses on evaluating new investments.
Vanessa joined Frazier Healthcare Partners in 2018, where she focuses on evaluating investments and creating new ventures in life sciences. She helped lead Frazier’s investment in MBX Biosciences, Seraxis, Mirum Pharmaceuticals (NASDAQ: MIRM) and Tarsus Pharmaceuticals (NASDAQ: TARS), and holds board observer roles in several companies.
Prior to joining Frazier, Vanessa was in Corporate Development at Gilead Sciences, where she structured and led the negotiation of licenses, collaborations, and acquisitions across therapeutic areas. Previously, Vanessa was a Business Development Manager at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where she led the evaluation and recommendation of licensing and acquisition opportunities for Janssen's $3.2B Infectious Disease Franchise. In addition, Vanessa worked for Morgan Stanley in the Equity Research Division with a focus on public biotech investments.
Vanessa holds a B.S. in Chemical Engineering from MIT and an M.B.A. from the Kellogg School of Management at Northwestern University.
Northwestern University (M.B.A.)